Clinical Trials Directory

Trials / Completed

CompletedNCT03574688

The Hydration to Optimize Metabolism (H2O Metabolism) Pilot Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Region Skane · Academic / Other
Sex
All
Age
20 Years – 75 Years
Healthy volunteers
Accepted

Summary

This study evaluates increased hydration (1.5 L of water daily during 6 weeks) on top of habitual water intake in the lowering of the vasopressin marker copeptin and in the lowering of plasma glucose concentration in adults with signs of low water intake at recruitment (elevated levels of copeptin, high urine osmolality, low urine volume).

Detailed description

High plasma concentration of vasopressin (i.e. antidiuretic hormone) is a novel and independent risk factor for type 2 diabetes, the metabolic syndrome, cardiovascular disease and premature death. The main physiological role of vasopressin is to maintain constant plasma osmolality. Previous studies in rats and a Mendelian randomization study in humans suggest causality between elevated vasopressin concentration and elevated plasma glucose concentration. As vasopressin can be suppressed by increasing water intake, the investigators hypothesize that water supplementation in individuals with high vasopressin can lower plasma glucose and prevent diabetes. The aim of this pilot study is to test if six weeks of water supplementation of 1.5 Liters of extra water per day in low-drinkers with high copeptin can significantly alter hydration markers in general and reduce plasma copeptin in particular. Furthermore, the investigators also aim at investigating whether this 6-week water intervention can significantly reduce fasting plasma glucose concentration.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTWaterIncreased daily water intake with 1.5 Liters of water per day on top of habitual water intake.

Timeline

Start date
2017-02-02
Primary completion
2017-07-25
Completion
2017-07-25
First posted
2018-07-02
Last updated
2018-07-03

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT03574688. Inclusion in this directory is not an endorsement.